<DOC>
	<DOCNO>NCT01116830</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled parallel group study assess effect biomarkers measure cognitive dysfunction , clinical efficacy safety RO4917838 participant schizophrenia schizoaffective disorder . Participants randomize receive either RO4917838 ( 10 milligram [ mg ] daily orally ) placebo 6 week , addition stable antipsychotic medication . Anticipated time study treatment 6 week .</brief_summary>
	<brief_title>A Study Effect RO4917838 Biomarker Measures Cognitive Dysfunction Participants With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder ( base screening test ) Medically stable 1 month psychiatrically stable without symptom exacerbation 6 week prior baseline On stable treatment maximum 2 antipsychotic Change regimen psychotropic sleep medication within 1 month Treatment ( &gt; ) 1 mood stabilizer antidepressant Use clozapine within 2 month Bipolar disorder , mild anxiety disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>